MiMedx Q2 net sales up 13%, beat expectations

MiMedx

30/07/2025 21:10

Overview

MiMedx Q2 net sales rise 13% yr/yr to $99 mln, beating analyst expectations

Adjusted EBITDA for Q2 was $24 mln, or 25% of net sales

Outlook

MiMedx expects 2025 net sales growth in low double-digits

Company anticipates 2025 adjusted EBITDA margin above 20%

MiMedx engaging with CMS on reimbursement reforms

Result Drivers

WOUND PRODUCT SALES - Driven by 12% growth, supported by newer products CELERA™ and EMERGE™

SURGICAL PRODUCT SALES - Increased 15% with contributions from AMNIOFIX®, AMNIOEFFECT®, and HELIOGEN™

GROSS MARGIN DECLINE - Decrease attributed to production variances and product mix

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Beat
$98.60 mln
$90.60 mln (5 Analysts)
Q2 EPS
$0.06
Q2 Net Income
$9.62 mln
Q2 Gross Profit
$79.92 mln
Q2 Operating Income
$12.37 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for MiMedx Group Inc is $12.00, about 44.4% above its July 29 closing price of $6.67

The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 25 three months ago

Press Release: ID:nGNX1tynn2

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)